Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock

CompletedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Cardiogenic ShockCardiorenal SyndromeAcute Kidney Failure
Interventions
DRUG

Levosimendan

Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.

All Listed Sponsors
lead

University of Zurich

OTHER

NCT04917497 - Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock | Biotech Hunter | Biotech Hunter